Provisional quality control parameters and interpretive criteria for testing susceptibility ofStreptococcus pneumoniae andHaemophilus influenzae to quinupristin/dalfopristin (RP59500)
- 1 March 1998
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 17 (3) , 197-201
- https://doi.org/10.1007/bf01691118
Abstract
Studies were undertaken to select tentative criteria for susceptibility testing of quinupristin/dalfopristin againstStreptococcus pneumoniae andHaemophilus influenzae. Against 612 isolates ofStreptococcus pneumoniae, MICs of quinupristin/dalfopristin were ≤1.0 μg/ml for all but one strain. With a tentative MIC breakpoint of either ≤ 1.0 μg/ml or ≤2.0 μg/ml for susceptible, a disk diffusion zone diameter breakpoint of ≥19 mm embraced all but two of the susceptible pneumococci; ≥16 mm included all strains. ForHaemophilus influenzae, MICs of quinupristin/dalfopristin clustered near the tentative breakpoints; 91.5% of the MICs were 2.0 to 8.0 μg/ml. This precluded satisfactory performance of the disk diffusion test in discriminating between resistant and susceptible isolates unless MIC breakpoints are modified for this species: clinical experience will be needed before that can be justified. Based on data from a multilaboratory study, the following quality control limits are proposed forStreptococcus pneumoniae ATCC 49619 when testing quinupristin/dalfopristin: 0.25 to 1.0 μg/ml for broth microdilution tests and 19 to 24 mm for disk diffusion tests. For tests ofHaemophilus influenzae ATCC 29247, MIC limits are 2.0 to 16 μg/ml; disk tests were very reproducible but are not yet recommended.Keywords
This publication has 8 references indexed in Scilit:
- Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests.Journal of Antimicrobial Chemotherapy, 1997
- In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and EnterococciDiagnostic Microbiology and Infectious Disease, 1995
- In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogensAntimicrobial Agents and Chemotherapy, 1995
- Quinupristin/Dalfopristin: Spectrum of Activity, Pharmacokinetics, and Initial Clinical ExperienceMicrobial Drug Resistance, 1995
- RP 59500, a new streptogramin highly active against recent isolates of North American staphylococciDiagnostic Microbiology and Infectious Disease, 1993
- In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC of the components of a semisynthetic streptogramin, RP 59500Journal of Antimicrobial Chemotherapy, 1992
- The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combinationJournal of Antimicrobial Chemotherapy, 1992
- In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococciAntimicrobial Agents and Chemotherapy, 1991